A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
NCT ID: NCT05467553
Last Updated: 2022-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
30 participants
INTERVENTIONAL
2023-02-24
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group 1: TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
Group 2: Ursodeoxycholic Acid (UDCA)\* 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
Both groups will have a post-treatment follow-up of 24 weeks.
\*: Dose of Ursodeoxycholic Acid (UDCA) will be determined by weight at Day 1 (TW0) in 2-4 divided doses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAF and P1101 combination therapy with UDCA
Ursodeoxycholic Acid (UDCA) 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
Ursodeoxycholic acid
Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
Ropeginterferon alfa-2b
P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
Tenofovir Alafenamide
TAF 25 mg PO QD for 60 weeks
TAF and P1101 combination therapy without UDCA
TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg sub-cutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
Ropeginterferon alfa-2b
P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
Tenofovir Alafenamide
TAF 25 mg PO QD for 60 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ursodeoxycholic acid
Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
Ropeginterferon alfa-2b
P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
Tenofovir Alafenamide
TAF 25 mg PO QD for 60 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Interferon treatment naïve.
3. Willing and able to provide written informed consent.
4. Age 20-75 years old; subjects who are over 70 years of age must be in generally good health.
5. Laboratory test results before study entry: WBC ≥ 3,000/mm3; ANC ≥ 1,500/mm3; Platelet ≥ 90,000/mm3; Hemoglobin ≥ 10g/dL; e-GFR ≥ 60mL/min.
6. ECG without clinically significant abnormalities before study entry.
7. Be able to attend all scheduled visits and to comply with all study procedures.
8. Patients with anti-HCV(+) or anti-HIV(+) can be enrolled if:
1. anti-HCV(+) with undetectable HCV RNA ≥ 3 months.
2. anti-HIV(+) with undetectable HIV viral load (either with or without Highly Active Anti- Retroviral Therapy, HAART).
Exclusion Criteria
2. Clinically significant vital sign abnormalities, uncontrolled hypertension, or fever \[body temperature \>38 degrees Celsius\].
3. History of significant alcohol or drug abuse within 6 months prior to the screening visit (alcohol consumption of more than 14 units of alcohol per week \[1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol\]) or refusal to abstain from alcohol or illicit drugs throughout the study.
4. Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bi-polar disorder, schizophrenia, suicidal ideation or history of suicidal attempt), neurological, cardiovascular, pulmonary, hematologic, immunologic, autoimmune diseases, thyroid or other endocrine diseases, metabolic (e.g. diabetes mellitus with HbA1C \> 8.0%) or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias.
5. Pregnant subject; female subject who are breast feeding or lactating; female subject or the spouse of male subject, with child-bearing potential who is unwilling or unable to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices throughout the study.
6. History of severe allergic or hypersensitivity reactions, e.g. hypersensitivity to the active substance or to any of the excipients of ropeginterferon alfa 2b, ursodeoxycholic acid, tenofovir disoproxil fumarate and tenofovir alafenamide.
7. Therapy with any systemic anti-viral treatment, anti-neoplastic, or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug.
8. A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis.
9. Body organ transplant or taking immunosuppressant.
10. Use of an investigational drug within 4 weeks prior to the first dose of the study drug.
11. History of malignancy diagnosed or treated within 5 years prior to screening (except for localized treatment of squamous or non-invasive basal cell skin cancers; cervical carcinoma in situ); cancer survivors not on maintenance therapy within the past 5 years.
12. History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia).
13. Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within 3 months prior to screening.
14. Clinically significant medical conditions known to interfere absorption, distribution, metabolism or excretion of the study drugs.
15. Decompensated liver disease, which includes but not limited to the following: total bilirubin ≥ 2 mg/dL (except in Gilbert syndrome), direct bilirubin ≥ 2X ULN, albumin level \< 3.5 g/dL, INR ≥ 1.5; clinical evidence of ascites, liver decompensation, hepatic encephalopathy, oesophageal varices or cirrhosis as identified by ultrasound or any other examination before study entry.
16. Significant steatohepatitis by ultrasound or other examination at the discretion of investigator.
17. Other form of significant chronic liver diseases, except those mentioned above.
18. Significant or major fundoscopic findings at screening including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilloedema, optic atrophy, microaneurysms and macu-lar changes.
19. Patients with complete biliary obstruction, chololithiasis, severe pancreatic disease or peptic ulcer.
20. Patients treated by monotherapy of telbivudine/TDF/TAF/adefovir dipivoxil or any other combination therapy with telbivudine/TDF/TAF/adefovir dipivoxil within 1 month prior to screening.
21. Patient who vaccination with any live attenuated vaccine within 1 month prior to screening.
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PharmaEssentia
INDUSTRY
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pei-Jer Chen
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Medical University Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Pei-Jer Chen
Role: primary
Yi-Wen Huang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P1101-HDV
Identifier Type: OTHER
Identifier Source: secondary_id
202108021MIPD
Identifier Type: -
Identifier Source: org_study_id